FMR LLC trimmed its holdings in shares of MediciNova, Inc. (NASDAQ:MNOV) by 7.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,183,300 shares of the biopharmaceutical company’s stock after selling 99,499 shares during the period. FMR LLC owned approximately 3.37% of MediciNova worth $6,224,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in MNOV. Northern Trust Corp lifted its holdings in shares of MediciNova by 10.6% during the second quarter. Northern Trust Corp now owns 368,599 shares of the biopharmaceutical company’s stock valued at $1,939,000 after purchasing an additional 35,331 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of MediciNova by 88.9% during the second quarter. SG Americas Securities LLC now owns 61,930 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 29,153 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of MediciNova during the second quarter valued at approximately $137,000. Vanguard Group Inc. lifted its holdings in shares of MediciNova by 1.0% during the second quarter. Vanguard Group Inc. now owns 1,197,716 shares of the biopharmaceutical company’s stock valued at $6,300,000 after purchasing an additional 12,249 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in shares of MediciNova by 7.2% during the second quarter. TIAA CREF Investment Management LLC now owns 90,295 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 6,035 shares during the last quarter. Hedge funds and other institutional investors own 21.74% of the company’s stock.
MediciNova, Inc. (NASDAQ:MNOV) opened at $6.26 on Friday. MediciNova, Inc. has a 1-year low of $4.40 and a 1-year high of $7.85.
WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/medicinova-inc-mnov-shares-sold-by-fmr-llc.html.
In other news, Director Yoshio Ishizaka purchased 5,000 shares of MediciNova stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average price of $5.17 per share, with a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $25,850. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.20% of the stock is owned by company insiders.
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with MarketBeat.com's FREE daily email newsletter.